REDWOOD CITY, Calif., May 16,
2012/PRNewswire/ -- Genomic Health,
Inc. (Nasdaq: GHDX) today announced that results from
18 separate studies covering breast, colon and prostate
cancers will be presented at the American Society of
Clinical Oncology (ASCO) 2012 Annual Meeting, reflecting
the company's ongoing commitment to the research,
development and delivery of innovative diagnostic tests
to help individualize cancer treatment decisions.
The annual meeting is taking place June 1-5,
2012in Chicago, Illinois.
Key study results to be presented at the meeting include:
-
Additional data on the clinical value of the Oncotype
DX DCIS Score™
-
Further validation of the Oncotype DX colon cancer test
-
Company's first prostate needle biopsy study
-
First Oncotype DX breast cancer treatment decision
impact study results from Canadaand
France
-
Multiple studies reconfirming the clinical utility and
cost effectiveness of the Oncotype DX breast cancer
test
The majority of ASCO Annual Meeting abstracts are now
publicly available on ASCO's website: www.asco.org.
Presentation details are as follows (all times are in
Central Time):
DCIS Breast Cancer
Tuesday, June 5, 2012
Oral Presentation: "Correlation between the DCIS
Score and traditional clinicopathologic features in the
prospectively designed E5194 clinical validation
study" (Abstract #1005)
-
Presenter:Sunil S. Badve, Indian
University School of Medicine
-
Session Time and Location:11:15 AM-
11:30 AM; E Hall D1
Colon Cancer
Friday, June 1, 2012
Poster Discussion: "Validation of the 12-gene colon
cancer recurrence score (RS) in NSABP C-07 as a predictor
of recurrence in stage II and III colon cancer patients
treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin
(FU+Ox)" (Abstract #3512)
-
Presenter: Michael O'Connell, MD, National Surgical
Adjuvant Breast and Bowel Project and Allegheny General
Hospital Cancer Center
-
Poster Discussion Session Time and Location:1
PM- 5 PM; E450b; E Arie Crown
Theater
-
Poster Board: #4
Monday, June 4, 2012
Poster Session: "Effect of the 12-gene colon cancer
assay results on treatment recommendations in patients
with stage II colon cancer"(Abstract #3626)
-
Presenter:Thomas H. Cartwright, MD, Ocala
Oncology
-
Session Time and Location:8 AM- 12
PM; S Hall A2
-
Poster Board: #37G
Prostate Cancer
Monday, June 4, 2012
Poster Discussion: "Development of a needle
biopsy-based genomic test to improve discrimination of
clinically aggressive from indolent prostate cancer"
(Abstract #4560)
-
Presenter:Eric A. Klein, MD, Cleveland
Clinic
-
Poster Discussion Session Time and Location:8
AM- 12 PM; E450a
-
Poster Board: #14
Invasive Breast Cancer
Saturday, June 2, 2012
Poster Session: "Prospective comparison of
recurrence score and independent central pathology
assessment of prognostic tools in early breast cancer
(BC): focus on HER2, ER, PR, Ki-67 results from the Phase
III WSG-Plan B trial" (Abstract #552)
-
Presenter: Oleg Gluz, MD, West German
Study Group
-
Session Time and Location: 8 AM- 12
PM; S Hall A2
-
Poster Board: #3C
Poster Session: "Prospective study of the impact of
using the 21-gene recurrence score assay on clinical
decision making in women with estrogen receptor-positive,
HER2-negative, early-stage breast cancer in
France" (Abstract #568)
-
Presenter: Joseph Gligorov, MD, PhD, Tenon
Hospital, Paris
-
Session Time and Location : 8 AM- 12
PM; S Hall A2
-
Poster Board: #5C
Poster Session: "Evaluation of Oncotype DX testing
and subsequent patterns of care in patients (pts) with
early-stage breast cancer (ESBC)" (Abstract #569)
-
Presenter: Meghan Fitzgerald, MPH, MBA,
Cardinal Health Specialty Solutions
-
Session Time and Location: 8 AM- 12
PM; S Hall A2
-
Poster Board: #5D
Poster Session: "Obesity at diagnosis and breast
cancer (BC) recurrence risk based on the 21-gene assay
recurrence score (RS)" (Abstract #555)
-
Presenter: Kimberly Ridolfi, MD,
University of Wisconsin
-
Session Time and Location: 8 AM- 12
PM; S Hall A2
-
Poster Board: #3F
Poster Session: "Impact of exogenous female hormone
use (EHU) on breast cancer (BC) recurrence as assessed by
the 21-gene assay (Oncotype DX)" (Abstract #563)
-
Presenter: Wendy M. Ledesma, MD,
University of Wisconsin
-
Session Time and Location: 8 AM- 12
PM; S Hall A2
-
Poster Board: #4F
Poster Session: "Evaluation of variables that may
impact chemotherapy (CT) administration after
determination of Oncotype DX (ODX) Recurrence Score
(RS)" (Abstract #571)
-
Presenter: Kristina E. Bowen, MD, Georgia
Cancer Specialists
-
Session Time and Location: 8 AM- 12
PM; S Hall A2
-
Poster Board: #5F
Poster Session: "A Prospective clinical utility
study of the impact of the 21-gene Recurrence Score assay
(Oncotype DX) in Estrogen Receptor Positive (ER+) Node
Negative (pN0) Breast Cancer in Academic Canadian
Centers" (Abstract #549)
-
Presenter: James A. Davidson, MD, British
Columbia Cancer Agency
-
Session Time and Location: 8 AM- 12
PM; S Hall A2
-
Poster Board: #2G
Sunday, June 3, 2012
Poster Discussion: "Cost-effectiveness of the
21-gene recurrence core assay in the setting of
multifactorial decision making for chemotherapy in
early-stage breast cancer" (Abstract #1525)
-
Presenter: Shelby D. Reed, PhD, Duke
University
-
Poster Session Time and Location: 8 AM-
12 PM; S102
-
Poster Board: #14
Monday, June 4, 2012
Poster Session: "Relationship between Oncotype DX
testing and the use of chemotherapy in high-risk patients
(pts)" (Abstract #6098)
-
Presenter: Winston Wong, PharmD, CareFirst
BlueCross BlueShield
-
Session Time and Location: 1:15 PM-
5:15 PM; S Hall A2
-
Poster Board: #8G
Poster Session: "Rural vs urban differences among
patients (pts) with hormone-receptor positive (HR+)
breast cancer (BC) and a 21-gene assay recurrence score
(RS)" (Abstract #6063)
-
Presenter: Molly Andreason, BS,
University of Wisconsin-Madison
-
Session Time and Location: 1:15 PM-
5:15 PM; S Hall A2
-
Poster Board: #4D
Poster Discussion: "10-year update of E2197: Phase
III doxorubucin/docetaxel (AT) vs
doxorubicin/cyclophosphamide (AC) adjuvant treatment of
LN + and high risk LN - breast cancer and the comparison
of the prognostic utility of the 21-gene recurrence score
(RS) with clinicopathologic features" (Abstract
#1021)
-
Presenter: Joseph A. Sparano, MD, Albert
Einstein Cancer Center-Montefiore Medical Center
-
Poster Session Time and Location: 1:15 PM-
5:15 PM; E450b
-
Poster Board: #13
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is a global
health company that provides actionable genomic
information to personalize genomic health decisions. The
company's lead product, the Oncotype DX® breast
cancer test, has been shown to predict the likelihood of
chemotherapy benefit as well as recurrence in
invasive
breast cancer and has been shown to predict the
likelihood of recurrence in ductal carcinoma in situ
(DCIS). In addition to this widely adopted test, Genomic
Health provides the Oncotype DX colon cancer test, the
first multigene expression test developed for the
assessment of risk of recurrence in patients with stage
II disease. As of March 31, 2012, more than
10,000 physicians in over 65 countries had ordered more
than 275,000 Oncotype DX tests. Genomic Health has a
robust pipeline focused on developing tests to optimize
the treatment of prostate and renal cell cancers, as well
as additional treatment decisions in breast and colon
cancers. The company is based in Redwood
City, Californiawith European headquarters in
Geneva, Switzerland. For more
information, please visit, www.GenomicHealth.com.
To learn more about Oncotype DX tests, visit: www.OncotypeDX.com and
www.mybreastcancertreatment.org.
Forward Looking Statement: This press release contains
forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995,
including statements relating to our ability to generate
similar results in further studies; the ability of any
tests the company may develop to optimize cancer
treatment; the applicability of clinical study results to
actual outcomes; our ability to develop and launch a test
for prostate cancer in 2013; the ability of the
company to develop additional tests in the future; the
scope, success or results of clinical trials and the
timing of such activities; and the ability of the
company's tests to impact clinical practice.
Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ
materially and reported results should not be considered
as an indication of future performance. These risks and
uncertainties include, but are not limited to: the risks
and uncertainties associated with the regulation of our
tests; the risks associated with competition; the
applicability of clinical study results to actual
outcomes; the risks associated with the commercialization
of current and future products; the risks and potential
delays associated with such studies; and the other risks
set forth in the company's filings with the
Securities and Exchange Commission, including the risks
set forth in the company's Quarterly Report on Form
10-Q for the quarter ended March 30, 2012.
These forward-looking statements speak only as of the
date hereof. Genomic Health disclaims any obligation to
update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX and
Recurrence Score are trademarks or registered trademarks
of Genomic Health, Inc. All other trademarks and service
marks are the property of their respective owners.
SOURCE Genomic Health, Inc.
Recommend:
